Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Avage Articles

Allergan plans extra trial

13 June 2005

Stock Commentary - New York

14 February 2005

Disappointing news for Allergan's Tazorac

4 October 2004

Stock Commentary - New York

4 October 2004

Allergan and PediaMed enter pediatrics copromotion for Tazorac

2 August 2004

Stock Commentary - New York

26 July 2004

Oral formulation of Allergan's tazarotene rejected by US FDA panel

19 July 2004

Stock Commentary - New York

19 July 2004

Pierre Fabre and Allergan to develop psoriasis nail varnish

15 March 2004

US FDA de facto ban on dual trademarks for drugs "unwise and arguably illegal"

12 May 2003

Allergan's Tazorac effective in psoriasis

31 March 2003

Allergan completes oral tazarotene trials

17 March 2003

FDA approves Allergan's Tazorac cream

18 October 2001

Recordati: R&D pipeline update

10 August 1999

Bioglan deal with Allergan on Zorac

20 April 1999

Bioglan and Allergan form Zorac alliance

16 April 1999

Pierre Fabre licenses Zorac in Europe

11 February 1999

Trend For 1997 Strong Sales Continues In USA

5 February 1998

1997: Another Good Year For New Chemical Entities

6 January 1998

Allergan Pulls Out Of Peptech Collaboration

22 October 1997

Tazarotene - 1st Effective Topical Retinoid For Psoriasis?

18 September 1997

FDA Approves Allergan's Tazorac

19 June 1997

Allergan Announces R&D Pipeline Developments

5 May 1997

Allergan Launches Zorac In First Market

20 January 1997

Germany Approves Allergan's Zorac

23 December 1996

Allergan: Azelex

25 September 1995

Showing 1-26 of 26 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • SciClone gains China rights to Zensun's Neucardin
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • Elan makes "transformational" acquisitions and a divestment
  • HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • SciClone gains China rights to Zensun's Neucardin

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS